<DOC>
	<DOCNO>NCT00349973</DOCNO>
	<brief_summary>This 6-week , randomize , double blind , parallel group design , olanzapine-controlled trial oral dipyridamole symptomatic patient ( DSM IV ) diagnosis schizophrenia , schizoaffective schizophreniform disorder . This pilot study aim provide preliminary estimate whether effect size dipyridamole positive symptom , negative symptom , cognitive deficit differ schizophrenia patient treated dipyridamole , schizophrenia patient treat olanzapine . A total 30 subject recruit locally .</brief_summary>
	<brief_title>Clinical Trial Dipyridamole Schizophrenia</brief_title>
	<detailed_description>Since demonstrate success chlorpromazine treat psychosis the1950 's , pharmacotherapy schizophrenia focus mainly drug antidopaminergic action . These drug robust effect reality distortion disorganization symptom complex , minimal effect cognitive impairment , negative symptom , functional outcome quality life measure . Newer generation antipsychotic drug similar profile effect , advantage course depression , hostility , suicide , hospital readmission rate motor side effect measure . Side effect weight gain , increase cardiovascular stress diabetes risk associate new generation drug . A new class drug need address inadequate effectiveness side-effect disadvantage currently available pharmacological agent treatment schizophrenia . Recently , new treatment strategy use nicotinergic drug agonist glycine modulatory site glutamatergic N-methyl-D-aspartate ( NMDA ) receptor employ clinical trial mixed result . Our proposal focus clinically available adenosine agonist , dipyridamole , 6-week clinical trial . Published data suggest effectiveness dipyridamole treat psychosis add haloperidol treatment . The effectiveness dipyridamole alone treat schizophrenia symptom , although indirectly suggest several line evidence , test .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subjects age 1865 , male nonpregnant female ( birth control ) Diagnosis schizophrenia , schizoaffective schizophreniform disorder Ability give write informed consent Total BPRS score &gt; 27 Psychosis subscale score &gt; 7 Patients coagulative disorder , bleed diathesis currently anticoagulant , patient major medical illness ( include hypertension , angina , cardiovascular disease ) abnormal baseline ECG . Patients moderate severe mental retardation . Inability sign inform consent . Patients history serious violence ( e.g. , suicide attempt , assaultive behavior ) . Patients clozapine treatment within 6 week lead doubleblind phase . Patients history olanzapine nonresponse Positive Urine Toxicology Screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Positive symptom</keyword>
	<keyword>Negative symptom</keyword>
	<keyword>Cognitive deficit</keyword>
</DOC>